{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05826275",
            "orgStudyIdInfo": {
                "id": "TGN-S11"
            },
            "organization": {
                "fullName": "Toragen, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer",
            "officialTitle": "A Phase 1 Trial of TGN-S11 in Patients With Human Papillomavirus (HPV)-Associated Relapsed, Resistant or Metastatic Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "phase-trial-in-patients-with-human-papillomavirus-hpv-associated-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-06-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-29",
            "studyFirstSubmitQcDate": "2023-04-20",
            "studyFirstPostDateStruct": {
                "date": "2023-04-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-02",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Toragen, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade."
        },
        "conditionsModule": {
            "conditions": [
                "HPV Associated Cancers"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Phase I, dose escalation/dose expansion study. Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 55,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "To determine the MTD in patients with HPV-associated cancers",
                    "interventionNames": [
                        "Drug: TGN-S11"
                    ]
                },
                {
                    "label": "Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Dose Expansion Phase, in parallel one dose level lower than the highest dose deemed safe in Dose escalation with a PD-1 checkpoint blockade.",
                    "interventionNames": [
                        "Drug: TGN-S11",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "TGN-S11",
                    "description": "Small Molecule",
                    "armGroupLabels": [
                        "Dose Escalation",
                        "Dose Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "PD-1 checkpoint blockade",
                    "armGroupLabels": [
                        "Dose Expansion"
                    ],
                    "otherNames": [
                        "Keytruda"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum Tolerated Dose",
                    "description": "To determine the maximum tolerated dose (MTD) of TGN-S11 in patients with human papillomavirus (HPV)-associated relapsed, resistant, or metastatic cancer.",
                    "timeFrame": "12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "PK Parameters to determine the single dose",
                    "description": "Cmax",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Steady state pharmacokinetics (PK) of TGN-S11",
                    "description": "AUC",
                    "timeFrame": "30 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Prior histologically confirmed HPV-associated squamous cell carcinoma, which is relapsed, resistant, or metastatic\n* Life expectancy of at least 3 months\n* Dose Escalation Phase: patients who have experienced disease progression on Standard of Care Therapies\n\nExclusion Criteria:\n\n* Active CNS metastases\n* Have any history of seizure disorder or are taking prophylactic seizure medication\n* Have an active viral, bacterial, or fungal infection",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Julio Juarez",
                    "role": "CONTACT",
                    "phone": "6198407387",
                    "email": "jjuarez@toragen.com"
                },
                {
                    "name": "Neil J Clendeninn, MD, PhD",
                    "role": "CONTACT",
                    "phone": "8585297393",
                    "phoneExt": "1003",
                    "email": "nclendeninn@toragen.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Neil J Clendeninn, MD, PhD",
                    "affiliation": "Chief Medical Officer",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Khaleda Khan",
                            "role": "CONTACT",
                            "email": "kkhan@coh.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Icahn School of Medicine at Mount Sinai",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10128",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Omayra Sanchez",
                            "role": "CONTACT",
                            "email": "Omayra.Sanchez@mssm.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Melissa Shorter",
                            "role": "CONTACT",
                            "email": "mkshorter@mdanderson.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Company Website",
                    "url": "https://toragen.com/"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}